Allogene Therapeutics Reports First Quarter 2025 Financial Results and Business Update

Core Insights - Allogene Therapeutics is advancing its allogeneic CAR T product pipeline for cancer and autoimmune diseases, with a focus on pivotal trials and strategic partnerships to enhance patient outcomes [2][3][5] Program Updates - The ALPHA3 trial for cema-cel as a first-line consolidation therapy for large B-cell lymphoma (LBCL) is ongoing, with nearly 50 activated sites across the U.S. and approximately 240 patients being randomized [3][5] - The trial has faced delays in site readiness, shifting the timeline for lymphodepletion regimen selection and futility analysis to the first half of 2026 [4][5] - The RESOLUTION trial for ALLO-329 in autoimmune diseases is set to begin in mid-2025, with proof-of-concept data expected in the first half of 2026 [9] - The TRAVERSE trial for ALLO-316 in renal cell carcinoma (RCC) has completed enrollment, with updated results to be presented at the 2025 ASCO Annual Meeting [10] Financial Results - As of March 31, 2025, the company reported a net loss of $59.7 million, or$0.28 per share, with total operating expenses of $65.2 million [13][20] - Research and development expenses for Q1 2025 were$50.2 million, while general and administrative expenses were $15.0 million [13][20] - The company ended Q1 2025 with$335.5 million in cash, cash equivalents, and investments, extending its cash runway into the second half of 2027 through strategic cost realignment [12][22]